Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose TBI + TLI/ATG for HCT Engraftment
NCT03734601Phase 2Completed
- Sponsor
- Stanford University
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Stanford University. Primary endpoint: Full-dose Donor Chimerism at Day 28. Started Nov 2018; status: completed.
Beyond the preview
Go deeper on NCT03734601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734601.